
World's premier cancer institute faces crippling cuts and chaos
NCI, which has long benefited from enthusiastic bipartisan support, now faces an exodus of clinicians, scientists, and other staffers, some fired, others leaving in exasperation.
After years of accelerating progress that has reduced cancer deaths by a third since the 1990s, the institute has terminated funds nationwide for research to fight the disease, expand care, and train new oncologists. 'We use the word 'drone attack' now regularly,' one worker said of grant terminations. 'It just happens from above.'
The assault could well result in a perceptible slowing of progress in the fight against cancer.
Nearly 2 million Americans are diagnosed with malignancies every year. In 2023, cancer killed more than 613,000 people, making it the second leading cause of death after heart disease. But the cancer fight has also made enormous progress. Cancer mortality in the U.S. has fallen by 34% since 1991, according to the American Cancer Society. There are roughly 18 million cancer survivors in the country.
That trend 'we can very, very closely tie to the enhanced investment in cancer science by the U.S. government,' said Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy and a globally recognized expert on prostate cancer.
'We're winning,' Knudsen said. 'Why we would let up, I really don't understand.'
This article is based on interviews with nearly two dozen current and former NCI employees, academic researchers, scientists, and patients. KFF Health News agreed not to name some government workers because they are not authorized to speak to the news media and fear retaliation.
'It's horrible. It's a crap show. It really, really is,' said an NCI laboratory chief who has worked at the institute for three decades. He's lost six of the 30 people in his lab this year: four scientists, a secretary, and an administrator.
'If we survive I will be somewhat surprised,' he said.
After a mandate by the Department of Health and Human Services and the Department of Government Efficiency to slash contract spending by more than a third, the cancer institute is cutting contracts to maintain precious biological specimens used in their research, according to three scientists. 'The required contract cuts are going to be devastating,' a senior scientist said.
On the NCI campus in Bethesda, Maryland, scientists describe delays in getting essential supplies — 'literally anything that goes into a test tube or a petri dish,' a recently departed clinician said — because of staffing cuts and constant changes in policies about what they can order.
Even the websites that publish new evidence on cancer treatment and diagnosis aren't being updated, because HHS fired workers who managed them. And when NCI scientists do communicate with outsiders, what they say has been severely restricted, according to documents viewed by KFF Health News. Forbidden topics include mass firings, President Donald Trump's executive orders, and 'DEIA' – diversity, equity, inclusion, and accessibility.
The turmoil at the National Institutes of Health's largest arm could haunt the country and the world for years to come.
'I really, really don't understand what they're trying to achieve,' said Sarah Kobrin, chief of NCI's health systems and interventions research branch. 'It just doesn't make sense.'
'Efforts that are lifesaving now are being curtailed,' one scientist said. 'People will die.'
Initially, some workers said, they thought the cancer institute might be spared. HHS Secretary Robert F. Kennedy Jr. has called chronic disease — cancer is one — 'an existential threat' to the country. Cancer research, with multiple NCI-funded breakthroughs in genetics and immunotherapy, has sidestepped the political minefields around other public health issues, like vaccination.
'People who care about cancer might be the biggest lobby in the country,' said Paul Goldberg, editor and publisher of The Cancer Letter, which has monitored oncology science and policy since 1973.
Count Mike Etchamendy, 69, of Big Bear Lake, California, as part of that lobby. Since 2013 he's flown to the East Coast scores of times to participate in five clinical trials at the cancer wing of NIH's Clinical Center.
'They call it the House of Hope,' Etchamendy said. Between drugs, therapeutic vaccines, and expert treatment for his rare bone cancer, called chordoma, he said, he believes he's gained at least 10 years of life. He's proud to have served as a 'lab rat for science' and worries about NCI's future.
'People come from all over the world to learn there,' Etchamendy said. 'You cut funding there, you're going to cut major research on cancer.'
In response to a list of detailed questions from KFF Health News about the cuts and chaos at NCI, HHS spokesperson Andrew Nixon said the reporting amounted to a 'biased narrative' that 'misrepresents a necessary transformation at the National Cancer Institute.' Nixon declined to elaborate but said research into cancer and other health conditions continues to be a high priority 'for both NIH and HHS.'
'We are refocusing resources on high-impact, evidence-based research — free from ideological bias or institutional complacency. While change can be uncomfortable for those invested in the status quo, it is essential to ensure that NCI delivers on its core mission,' he said.
Much of NCI's work is authorized by the National Cancer Act of 1971, which expanded its mandate as part of President Richard Nixon's 'War on Cancer.' Three of four of the cancer institute's research dollars go to outside scientists, with most of the remainder funding more than 300 scientists on campus.
And Congress was generous. Harold Varmus, one of more than 40 Nobel laureates whose work was funded by NCI, said budgets were usually handsome when he was NIH director from 1993 through 1999. President Bill Clinton 'would say to me, 'I'd like to give you a bigger increase, Harold, but your friends in Congress will bring it up.' He'd offer me a 5% increase,' Varmus recalled, but 'I'd end up getting more like 10%' from Congress.
Congress appropriated $2 billion to NCI in fiscal 1993. By 2025, funding had risen to $7.22 billion.
During a May 19 town hall meeting with NIH staff members, Jay Bhattacharya, the institute's new director, equivocated when asked about funding cuts for research into improving the health of racial and ethnic minorities — cuts made under the guise of purging DEI from the government.
According to a recording of the meeting obtained by KFF Health News, Bhattacharya said the agency remained 'absolutely committed to advancing the health and well-being of every population, including minority populations, LGBTQ populations, and every population.'
Research addressing the health needs of women and minorities is 'an absolute priority of mine,' he said. 'We're going to keep funding that.' But a study considering whether 'structural racism causes poor health in minority populations' is 'not a scientific hypothesis.'
'We need scientific ideas that are actionable, that improve the health and well-being of people, not ideological ideas that don't have any chance of improving the health and well-being of people,' he said. That comment angered many staffers, several said in interviews. Many got up and walked out during the speech, while others, watching remotely, scoffed or jeered.
Several current and former NCI scientists questioned Bhattacharya's commitment to young scientists and minorities. Staffing cuts early in the year eliminated many recently hired NCI scientists. At least 172 National Cancer Institute grants, including for research aimed at minimizing health disparities among racial minorities or LGBTQ+ people, were terminated and hadn't been reinstated as of June 16, according to a KFF Health News analysis of HHS documents and a list of grant terminations by outside researchers.
Those populations have higher rates of certain cancer diagnoses and are more likely to be diagnosed later than white or heterosexual people. Black people are also more likely to die of many cancer types than all other racial and ethnic groups.
Jennifer Guida, a researcher who focuses on accelerated aging in cancer survivors, said she recently left NCI after a decade in part because of the administration's DEI orders. According to several workers and internal emails viewed by KFF Health News, those included an HHS edict in January to report their colleagues who worked on such issues, and flagging grants that included DEI-related terms because they didn't align with Trump's priorities.
'I'm not going to put my name attached to that. I don't stand for that. It's not OK,' said Guida, who added that it amounted to a 'scrubbing of science.'
Racial discrimination is one factor that contributes to accelerated aging. 'There are a growing number of cancer survivors in the U.S.,' Guida said, and 'a significant number of those people who will become cancer survivors are racial and ethnic minorities.'
'Those people deserve to be studied,' she said. 'How can you help those people if you're not even studying them?'
In May, NCI informed leaders of the Comprehensive Partnerships to Advance Cancer Health Equity, a program that links 14 large U.S. cancer centers with minority-serving colleges and universities, that their funding would be cut. The project's Notice of Funding Opportunity — the mechanism the government uses to award grants — had been suddenly taken offline, meaning NCI staffers couldn't award future funding, according to three sources and internal communications viewed by KFF Health News. These 'unpublishings' have often occurred without warning, explanation, or even notification of the grantee that no more money would be coming.
The cancer partnerships have trained more than 8,500 scientists. They're designed to address widely documented disparities in cancer care by having top medical schools place students from rural, poor, and minority-serving schools and community clinics in research, training, and outreach.
Research shows that patients from racial and ethnic minorities receive better medical care and have improved outcomes when their clinicians share their background.
'I'm from an immigrant family, the first to graduate in my family,' said Elena Martinez, professor of family medicine and public health at the University of California-San Diego, who leads one of the partnerships with colleagues at largely Hispanic Cal State-San Diego. 'I wouldn't be here without this kind of program, and there won't be people like me here in the future if we cut these programs.'
In early April, when the dust settled after mass firings across HHS, workers in NCI's communications office were relieved they still had their jobs.
It didn't last. A month later, HHS fired nearly all of them, three former workers said. Combined with retirements and other departures, a skeleton crew of six or seven remain of about 75 people. 'We were all completely blindsided,' a fired worker said. NCI leadership 'had no idea that this was happening.'
As a result, websites, newsletters, and other resources for patients and doctors about the latest evidence in cancer treatment aren't being updated. They include Cancer.gov and NCI's widely used Physician Data Query, which compile research findings that doctors turn to when caring for cancer patients.
Gary Kreps, founding director of the Center for Health and Risk Communication at George Mason University, said he relied on Physician Data Query when his father was diagnosed with advanced stomach cancer, taking PDQ printouts when he met with his dad's doctors. 'It made a huge difference,' Kreps said. 'He ended up living, like, another three years' — longer than expected — 'and enjoyed the rest of his life.'
As of May 30, banners at the top of the Cancer.gov and PDQ websites said, 'Due to HHS restructuring and reduction in workforce efforts, the information on this website may not be up to date and pages will indicate as such.' The banners are gone, but neither website was being updated, according to a fired worker with knowledge of the situation.
Outdated PDQ information is 'really very dangerous,' Kreps said.
Wiping out NCI's communications staff makes it harder to share complex and ever-changing information that doctors and patients need, said Peter Garrett, who headed NCI's communications before retiring in May. Garrett said he left because of concerns about political interference.
'The science isn't finished until it's communicated,' he said. 'Without the government playing that role, who's going to step in?'
Following court decisions that blocked some NIH grant cancellations or rendered them 'void' and 'illegal,' NIH official Michelle Bulls in late June told staffers to stop terminating grants. However, NCI workers told KFF Health News they continue to review grants flagged by NIH to assess whether they align with Trump administration priorities. Courts have ordered NIH to reinstate some terminated grants, but not all of them.
At NCI and across NIH, staffers remain anxious.
The White House wants Congress to slash the cancer institute's budget by nearly 40%, to $4.53 billion, as part of a larger proposal to sharply reduce NIH's fiscal 2026 coffers.
Bhattacharya has said he wants NIH to fund more big, breakthrough research. Major cuts could have the opposite effect, Knudsen said. When NCI funding shrinks, 'it's the safe science that tends to get funded, not the science that is game changing and has the potential to be transformative for cures.'
Usually the president's budget is dead on arrival in Congress, and members of both parties have expressed doubt about Trump's 2026 proposal. But agency workers, outside scientists, and patients fear this one may stick, with devastating impact.
It would force NCI to suspend all new grants or cut existing grants so severely that the gaps will close many labs, said Varmus, who ran NCI from 2010 to 2015. Add that to the impact on NCI's contracts, clinical trials, internal research, and salaries, he said, and 'you can reliably say that NCI will be unable to keep up in any way with the promise of science that's currently underway.'
The NCI laboratory chief, who has worked at the institute for decades, put it this way: 'If the 40% budget cut passes in Congress, it will destroy clinical research at NCI.'
KFF Health News Correspondent Rae Ellen Bichell contributed to this report.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
10 minutes ago
- Associated Press
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Jul 28, 2025-- Regulatory News: MaaT Pharma(EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. View source version on CONTACT: EIB Andrea Morawski,[email protected], mobile: +352 691 284 349 Website: Press Office:[email protected] Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected] Agency – U.S. Media Relations Heather Shea Media relations for MaaT Pharma +1 617-286-2013 [email protected] KEYWORD: FRANCE EUROPE INDUSTRY KEYWORD: ONCOLOGY HEALTH STEM CELLS CLINICAL TRIALS PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY SOURCE: MaaT Pharma Copyright Business Wire 2025. PUB: 07/28/2025 01:30 AM/DISC: 07/28/2025 01:30 AM
Yahoo
30 minutes ago
- Yahoo
Several US executives to visit China this week: sources
By Laurie Chen BEIJING (Reuters) -A high-level delegation of American executives will travel to China this week to meet senior Chinese officials in a trip organised by the U.S.-China Business Council (USCBC), two sources with knowledge of the visit told Reuters on Monday. The visit coincides with the latest round of U.S.‑China trade negotiations in Sweden, where China's Vice Premier He Lifeng is meeting U.S. officials from July 27 to July 30 for a new round of economic and trade talks. The delegation will be led by FedEx Chief Executive Rajesh Subramaniam, the council's board chair, one of the sources briefed on the trip said. The South China Morning Post first reported the visit on Sunday, saying that executives from firms including Boeing would be part of the delegation. Reuters could not confirm other CEO members of the delegation or which Chinese officials they would meet. Boeing declined to comment on the trip and deferred to USCBC. The U.S. government was not involved in the organisation of the visit, one of the sources said. The trip comes as Beijing and Washington work towards a summit between the two countries' leaders later this year, probably around the time of the APEC forum in South Korea October 26 - November 1, sources previously told Reuters. USCBC did not respond immediately to a request for comment. The business lobby previously organised similar visits to China by American CEO delegations in 2023 and 2024. The 2024 trip, also led by Subramaniam, included meetings with He and Foreign Minister Wang Yi, where executives discussed issues including market access. China faces an August 12 deadline to reach a durable deal with the White House or risk higher U.S. tariffs. U.S. officials are likely to extend the deadline by another 90 days as both sides work towards a more comprehensive deal, sources previously told Reuters. An extension of that length would prevent further escalation and help create conditions for the potential meeting between Trump and Chinese President Xi Jinping. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
30 minutes ago
- Yahoo
Trump pauses export controls to bolster China trade deal, FT says
(Reuters) -The U.S. has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year, the Financial Times said on Monday. The industry and security bureau of the Commerce Department, which oversees export controls, has been told in recent months to avoid tough moves on China, the newspaper said, citing current and former officials. Reuters could not immediately verify the report. The White House and the department did not respond to Reuters' requests for comment outside business hours. Top U.S. and Chinese economic officials are set to resume talks in Stockholm on Monday to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies. Tech giant Nvidia said this month it would resume sales of its H20 graphics processing units (GPU) to China, reversing an export curb the Trump administration imposed in April to keep advanced AI chips out of Chinese hands over national security concerns. The planned resumption was part of U.S. negotiations on rare earths and magnets, Commerce Secretary Howard Lutnick has said. The paper said 20 security experts and former officials, including former deputy US national security adviser Matt Pottinger, will write on Monday to Lutnick to voice concern, however. "This move represents a strategic misstep that endangers the United States' economic and military edge in artificial intelligence," they write in the letter, it added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data